NextCure Key Executives
This section highlights NextCure's key executives, including their titles and compensation details.
Find Contacts at NextCure
(Showing 0 of )
NextCure Earnings
This section highlights NextCure's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
$0.33
Stock Price
$9.23M
Market Cap
43
Employees
Beltsville, MD
Location
Financial Statements
Access annual & quarterly financial statements for NextCure, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $22.38M |
| Cost of Revenue | $- | $3.68M | $4.48M | $4.30M | $46.55K |
| Gross Profit | $- | $-3.68M | $-4.48M | $-4.30M | $22.33M |
| Gross Profit Ratio | 0.00% | - | - | - | 99.79% |
| Research and Development Expenses | $41.49M | $47.93M | $54.20M | $50.19M | $46.55M |
| General and Administrative Expenses | $15.72M | $19.71M | $21.71M | $20.57M | $17.05M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $15.72M | $19.71M | $21.71M | $20.57M | $17.05M |
| Other Expenses | $2.54M | $- | $1.18M | $1.38M | $4.62M |
| Operating Expenses | $59.75M | $67.64M | $75.91M | $70.77M | $63.60M |
| Cost and Expenses | $59.75M | $67.64M | $75.91M | $70.77M | $63.60M |
| Interest Income | $- | $- | $1.17M | $1.32K | $4.55K |
| Interest Expense | $- | $- | $- | $77.00K | $183.00K |
| Depreciation and Amortization | $2.87M | $3.68M | $4.48M | $4.30M | $3.41M |
| EBITDA | $-54.34M | $-59.04M | $-70.25M | $-65.01M | $-37.81M |
| EBITDA Ratio | - | - | - | - | -168.97% |
| Operating Income | $-59.75M | $-67.64M | $-75.91M | $-70.77M | $-41.23M |
| Operating Income Ratio | - | - | - | - | -184.22% |
| Total Other Income Expenses Net | $4.09M | $4.91M | $1.18M | $1.38M | $4.62M |
| Income Before Tax | $-55.65M | $-62.72M | $-74.73M | $-69.39M | $-36.60M |
| Income Before Tax Ratio | - | - | - | - | -163.57% |
| Income Tax Expense | $- | $- | $-5.30M | $6.96M | $-3.41M |
| Net Income | $-55.65M | $-62.72M | $-69.43M | $-69.39M | $-33.19M |
| Net Income Ratio | - | - | - | - | -148.32% |
| EPS | $-1.99 | $-2.25 | $-2.50 | $-2.51 | $-1.21 |
| EPS Diluted | $-1.99 | $-2.25 | $-2.50 | $-2.51 | $-1.21 |
| Weighted Average Shares Outstanding | 27.96M | 27.84M | 27.74M | 27.62M | 27.53M |
| Weighted Average Shares Outstanding Diluted | 27.96M | 27.84M | 27.74M | 27.62M | 27.53M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $6.28M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $22.38M |
| Cost of Revenue | $- | $- | $701.00K | $940.00K | $824.00K | $946.00K | $1.09M | $1.11M | $- | $1.02M | $- | $2.10M | $2.10M | $2.10M | $1.89M | $1.10M | $12.11M | $12.74M | $11.13M | $10.58M |
| Gross Profit | $- | $- | $-701.00K | $-940.00K | $5.46M | $-946.00K | $-1.09M | $-1.11M | $- | $-1.02M | $- | $-2.10M | $-2.10M | $-2.10M | $-1.89M | $-1.10M | $-12.11M | $-12.74M | $-11.13M | $11.80M |
| Gross Profit Ratio | - | 0.00% | - | - | 86.89% | - | - | - | - | - | - | - | - | - | - | - | -54097774599953.62% | - | - | 52.73% |
| Research and Development Expenses | $8.90M | $8.77M | $12.42M | $11.40M | $11.83M | $11.01M | $13.45M | $11.65M | $12.82M | $13.53M | $12.82M | $15.02M | $12.26M | $13.60M | $11.95M | $12.39M | $12.11M | $12.74M | $11.13M | $10.58M |
| General and Administrative Expenses | $3.55M | $3.73M | $4.08M | $4.36M | $3.96M | $4.61M | $5.71M | $5.42M | $4.95M | $5.71M | $5.30M | $5.75M | $4.81M | $4.91M | $6.01M | $4.85M | $4.13M | $4.66M | $4.67M | $3.59M |
| Selling and Marketing Expenses | $- | $- | $-701.00K | $3.42M | $-824.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $3.55M | $3.73M | $3.38M | $3.42M | $3.14M | $4.61M | $5.71M | $5.42M | $4.95M | $5.71M | $5.30M | $5.75M | $4.81M | $4.91M | $6.01M | $4.85M | $4.13M | $4.66M | $4.67M | $3.59M |
| Other Expenses | $- | $- | $1.09M | $1.20M | $1.32M | $1.32M | $1.30M | $975.00K | $- | $328.00K | $208.00K | $169.00K | $132.00K | $578.00K | $-35.00K | $701.00K | $776.00K | $1.03M | $1.29M | $1.52M |
| Operating Expenses | $12.46M | $12.49M | $15.79M | $14.82M | $14.97M | $15.62M | $19.16M | $17.07M | $17.77M | $19.24M | $18.13M | $20.77M | $17.07M | $18.51M | $17.95M | $17.23M | $16.24M | $17.40M | $15.80M | $14.17M |
| Cost and Expenses | $12.46M | $12.49M | $16.49M | $15.76M | $15.79M | $15.62M | $19.16M | $17.07M | $17.77M | $19.24M | $18.13M | $20.77M | $17.07M | $18.51M | $17.95M | $17.23M | $16.24M | $17.40M | $15.80M | $14.17M |
| Interest Income | $- | $- | $- | $- | $- | $1.32K | $1.30K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $674.00K | $700.00K | $701.00K | $940.00K | $824.00K | $946.00K | $1.09M | $1.11M | $1.01M | $1.02M | $1.04M | $2.10M | $2.10M | $2.10M | $1.89M | $1.10M | $990.00K | $885.00K | $787.00K | $751.00K |
| EBITDA | $-11.78M | $-11.79M | $-15.79M | $-14.97M | $-14.97M | $-14.67M | $-18.20M | $-16.11M | $-16.76M | $-18.22M | $-17.09M | $-19.71M | $-14.84M | $-16.77M | $-17.66M | $-16.13M | $-15.25M | $-16.51M | $-15.01M | $8.96M |
| EBITDA Ratio | - | - | - | - | -238.16% | - | - | - | - | - | - | - | - | - | - | - | -68133881490749.85% | - | - | 40.05% |
| Operating Income | $-12.46M | $-12.49M | $-16.49M | $-15.76M | $-15.79M | $-15.62M | $-19.16M | $-17.07M | $-17.77M | $-19.24M | $-18.13M | $-20.77M | $-17.07M | $-18.51M | $-17.95M | $-17.23M | $-16.24M | $-17.40M | $-15.80M | $-8.21M |
| Operating Income Ratio | - | - | - | - | -251.27% | - | - | - | - | - | - | - | - | - | - | - | -72557869335954.95% | - | - | -36.70% |
| Total Other Income Expenses Net | $852.00K | $955.00K | $1.09M | $-1.34M | $1.32M | $1.32M | $1.30M | $975.00K | $471.00K | $328.00K | $208.00K | $169.00K | $132.00K | $578.00K | $-35.00K | $701.00K | $776.00K | $1.03M | $1.29M | $1.52M |
| Income Before Tax | $-11.60M | $-11.54M | $-15.40M | $-17.11M | $-14.47M | $-14.30M | $-17.86M | $-16.10M | $-17.30M | $-18.91M | $-17.92M | $-20.60M | $-16.94M | $-17.93M | $-17.99M | $-16.53M | $-15.46M | $-16.37M | $-14.51M | $9.73M |
| Income Before Tax Ratio | - | - | - | - | -230.22% | - | - | - | - | - | - | - | - | - | - | - | -69090177853248.73% | - | - | 43.49% |
| Income Tax Expense | $- | $- | $- | $896.72K | $975.00K | $985.59K | $831.91K | $-975.00K | $- | $-328.00K | $-207.00K | $-169.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Income | $-11.60M | $-11.54M | $-15.40M | $-17.11M | $-14.47M | $-14.30M | $-17.86M | $-15.12M | $-17.30M | $-18.58M | $-17.71M | $-20.43M | $-16.94M | $-17.93M | $-17.99M | $-16.53M | $-15.46M | $-16.37M | $-14.51M | $9.73M |
| Net Income Ratio | - | - | - | - | -230.22% | - | - | - | - | - | - | - | - | - | - | - | -69090177853248.73% | - | - | 43.49% |
| EPS | $-0.41 | $-0.41 | $-0.55 | $-0.61 | $-0.52 | $-0.51 | $-0.64 | $-0.54 | $0.00 | $-0.67 | $-0.64 | $-0.74 | $-0.61 | $-0.65 | $-0.65 | $-0.60 | $-0.56 | $-0.59 | $-0.53 | $0.35 |
| EPS Diluted | $-0.41 | $-0.41 | $-0.55 | $-0.61 | $-0.52 | $-0.51 | $-0.64 | $-0.54 | $0.00 | $-0.67 | $-0.64 | $-0.74 | $-0.61 | $-0.65 | $-0.65 | $-0.60 | $-0.56 | $-0.59 | $-0.53 | $0.33 |
| Weighted Average Shares Outstanding | 27.98M | 27.98M | 27.97M | 27.90M | 27.91M | 27.84M | 27.83M | 27.77M | - | 27.75M | 27.74M | 27.71M | 27.62M | 27.62M | 27.61M | 27.60M | 27.55M | 27.55M | 27.52M | 27.51M |
| Weighted Average Shares Outstanding Diluted | 27.98M | 27.98M | 27.97M | 27.90M | 27.91M | 27.84M | 27.83M | 27.77M | - | 27.75M | 27.74M | 27.71M | 27.62M | 27.62M | 27.61M | 27.60M | 27.55M | 27.55M | 27.52M | 29.35M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $27.73M | $13.08M | $26.63M | $12.34M | $32.77M |
| Short Term Investments | $40.89M | $95.22M | $133.28M | $207.25M | $250.68M |
| Cash and Short Term Investments | $68.62M | $108.30M | $159.91M | $219.59M | $283.45M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $-700.00K | $- | $- |
| Other Current Assets | $3.19M | $4.43M | $4.07M | $8.23M | $4.53M |
| Total Current Assets | $71.81M | $112.72M | $163.98M | $227.82M | $287.98M |
| Property Plant Equipment Net | $8.72M | $13.43M | $16.91M | $13.99M | $15.81M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $1.81M |
| Tax Assets | $- | $- | $1.54M | $- | $- |
| Other Non-Current Assets | $332.00K | $1.88M | $1.73M | $577.00K | $1.05M |
| Total Non-Current Assets | $9.05M | $15.31M | $20.18M | $14.57M | $18.67M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $80.86M | $128.04M | $184.16M | $242.39M | $306.64M |
| Account Payables | $5.35M | $2.33M | $4.27M | $1.94M | $3.90M |
| Short Term Debt | $- | $656.00K | $518.00K | $- | $1.67M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $130.00K |
| Other Current Liabilities | $4.22M | $3.90M | $4.34M | $4.67M | $4.76M |
| Total Current Liabilities | $9.57M | $6.88M | $9.13M | $6.61M | $10.32M |
| Long Term Debt | $5.15M | $5.95M | $13.21M | $- | $1.81M |
| Deferred Revenue Non-Current | $- | $- | $-1.54M | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $1.54M | $- | $- |
| Other Non-Current Liabilities | $661.00K | $785.00K | $-5.71M | $2.39M | $792.00K |
| Total Non-Current Liabilities | $5.81M | $6.73M | $7.50M | $2.39M | $2.60M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $15.39M | $13.62M | $16.63M | $9.00M | $12.92M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K |
| Retained Earnings | $-380.14M | $-324.48M | $-261.76M | $-187.03M | $-117.64M |
| Accumulated Other Comprehensive Income Loss | $4.00K | $-222.00K | $-1.49M | $-663.00K | $779.00K |
| Other Total Stockholders Equity | $445.58M | $439.10M | $430.75M | $421.05M | $410.55M |
| Total Stockholders Equity | $65.47M | $114.42M | $167.53M | $233.39M | $293.72M |
| Total Equity | $65.47M | $114.42M | $167.53M | $233.39M | $293.72M |
| Total Liabilities and Stockholders Equity | $80.86M | $128.04M | $184.16M | $242.39M | $306.64M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $80.86M | $128.04M | $184.16M | $242.39M | $306.64M |
| Total Investments | $40.89M | $95.22M | $133.28M | $207.25M | $250.68M |
| Total Debt | $5.15M | $6.61M | $7.12M | $- | $3.47M |
| Net Debt | $-22.57M | $-6.48M | $-19.51M | $-12.34M | $-29.30M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $27.73M | $27.70M | $20.85M | $18.36M | $13.08M | $19.52M | $22.02M | $29.97M | $26.63M | $31.05M | $28.16M | $10.65M | $12.34M | $36.66M | $34.90M | $36.53M | $32.77M | $22.53M | $25.05M | $28.91M |
| Short Term Investments | $40.89M | $47.61M | $65.59M | $77.64M | $95.22M | $98.69M | $108.60M | $115.52M | $133.28M | $138.16M | $157.33M | $190.67M | $207.25M | $198.67M | $214.62M | $231.71M | $250.68M | $268.67M | $284.29M | $293.19M |
| Cash and Short Term Investments | $68.62M | $75.31M | $86.44M | $96.00M | $108.30M | $118.21M | $130.62M | $145.49M | $159.91M | $169.21M | $185.49M | $201.32M | $219.59M | $235.34M | $249.52M | $268.24M | $283.45M | $291.21M | $309.33M | $322.10M |
| Net Receivables | $- | $- | $- | $600.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $3.19M | $3.38M | $4.02M | $6.55M | $4.43M | $4.48M | $4.68M | $3.42M | $4.07M | $12.16M | $14.88M | $15.18M | $8.23M | $7.70M | $9.11M | $4.82M | $4.53M | $5.78M | $5.74M | $4.57M |
| Total Current Assets | $71.81M | $78.69M | $90.45M | $102.55M | $112.72M | $122.68M | $135.30M | $148.92M | $163.98M | $175.31M | $192.95M | $208.93M | $227.82M | $243.04M | $258.63M | $273.05M | $287.98M | $296.98M | $315.07M | $326.66M |
| Property Plant Equipment Net | $8.72M | $9.58M | $10.26M | $10.73M | $13.43M | $14.40M | $15.22M | $16.05M | $16.91M | $12.12M | $12.62M | $13.24M | $13.99M | $14.21M | $14.71M | $15.47M | $15.81M | $15.82M | $14.83M | $12.78M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $972.00K | $1.39M | $250.68M | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $1.38M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $332.00K | $2.07M | $1.87M | $1.88M | $1.88M | $2.85M | $2.86M | $2.82M | $3.27M | $2.47M | $801.00K | $574.00K | $577.00K | $581.00K | $1.05M | $1.05M | $-247.82M | $3.28M | $3.59M | $4.02M |
| Total Non-Current Assets | $9.05M | $11.65M | $12.13M | $12.61M | $16.69M | $17.25M | $18.08M | $18.87M | $20.18M | $14.59M | $13.42M | $13.81M | $14.57M | $14.79M | $16.73M | $17.91M | $18.67M | $19.10M | $18.42M | $16.81M |
| Other Assets | $- | $- | $- | $- | $-0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $80.86M | $90.34M | $102.59M | $115.16M | $129.42M | $139.94M | $153.38M | $167.79M | $184.16M | $189.91M | $206.37M | $222.75M | $242.39M | $257.82M | $275.36M | $290.96M | $306.64M | $316.08M | $333.49M | $343.47M |
| Account Payables | $5.35M | $3.61M | $5.08M | $4.49M | $2.33M | $2.60M | $2.81M | $1.92M | $4.27M | $1.85M | $2.27M | $2.80M | $1.94M | $2.95M | $1.35M | $2.02M | $3.90M | $186.00K | $2.44M | $2.26M |
| Short Term Debt | $796.00K | $- | $- | $- | $656.00K | $- | $- | $- | $518.00K | $- | $- | $- | $- | $- | $1.67M | $1.67M | $1.67M | $1.67M | $1.67M | $1.67M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $-276.00K | $-536.00K | $-787.00K | $- | $- | $- | $- | $- | $- | $- | $- | $6.43M | $- | $- | $- |
| Other Current Liabilities | $3.42M | $5.06M | $5.76M | $5.09M | $3.90M | $3.95M | $5.01M | $4.35M | $4.34M | $4.04M | $3.42M | $3.62M | $4.67M | $4.43M | $5.55M | $4.50M | $4.63M | $3.89M | $4.26M | $4.22M |
| Total Current Liabilities | $9.57M | $8.67M | $10.83M | $9.58M | $6.88M | $6.55M | $7.82M | $6.27M | $9.13M | $5.89M | $5.70M | $6.42M | $6.61M | $7.38M | $8.56M | $8.19M | $10.32M | $5.74M | $8.36M | $8.15M |
| Long Term Debt | $5.15M | $5.39M | $11.18M | $5.77M | $11.90M | $12.24M | $12.57M | $12.90M | $6.61M | $- | $- | $- | $- | $- | $972.00K | $1.39M | $1.81M | $2.22M | $2.64M | $3.06M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $15.95M | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $1.38M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-15.95M | $- | $- | $- |
| Other Non-Current Liabilities | $661.00K | $693.00K | $-4.87M | $755.00K | $-5.16M | $-5.30M | $-5.44M | $-5.58M | $899.00K | $2.48M | $2.48M | $2.39M | $2.39M | $2.22M | $2.22M | $2.22M | $792.00K | $776.00K | $571.00K | $507.00K |
| Total Non-Current Liabilities | $5.81M | $6.08M | $6.31M | $6.53M | $8.11M | $6.93M | $7.13M | $7.32M | $7.50M | $2.48M | $2.48M | $2.39M | $2.39M | $2.22M | $3.20M | $3.61M | $2.60M | $3.00M | $3.21M | $3.56M |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $-0 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $15.39M | $14.75M | $17.15M | $16.11M | $15.00M | $13.49M | $14.95M | $13.59M | $16.63M | $8.37M | $8.17M | $8.81M | $9.00M | $9.60M | $11.76M | $11.80M | $12.92M | $8.74M | $11.57M | $11.71M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $316.08M | $333.49M | $343.47M |
| Common Stock | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K | $28.00K |
| Retained Earnings | $-380.14M | $-368.53M | $-356.99M | $-341.59M | $-324.48M | $-310.01M | $-295.71M | $-277.86M | $-261.76M | $-244.46M | $-225.55M | $-207.63M | $-187.03M | $-170.09M | $-152.16M | $-134.17M | $-117.64M | $-102.18M | $-85.81M | $-71.30M |
| Accumulated Other Comprehensive Income Loss | $4.00K | $76.00K | $-86.00K | $-182.00K | $-222.00K | $-603.00K | $-925.00K | $-803.00K | $-1.49M | $-2.40M | $-2.34M | $-2.20M | $-663.00K | $-129.00K | $-195.00K | $179.00K | $779.00K | $1.30M | $1.94M | $-543.00K |
| Other Total Stockholders Equity | $445.58M | $444.02M | $442.49M | $440.79M | $439.10M | $437.04M | $435.04M | $432.83M | $430.75M | $428.37M | $426.06M | $423.74M | $421.05M | $418.41M | $415.92M | $413.12M | $410.55M | $408.19M | $405.76M | $403.57M |
| Total Stockholders Equity | $65.47M | $75.59M | $85.44M | $99.05M | $114.42M | $126.45M | $138.43M | $154.20M | $167.53M | $181.54M | $198.20M | $213.94M | $233.39M | $248.23M | $263.60M | $279.16M | $293.72M | $307.34M | $321.92M | $331.76M |
| Total Equity | $65.47M | $75.59M | $85.44M | $99.05M | $114.42M | $126.45M | $138.43M | $154.20M | $167.53M | $181.54M | $198.20M | $213.94M | $233.39M | $248.23M | $263.60M | $279.16M | $293.72M | $307.34M | $321.92M | $331.76M |
| Total Liabilities and Stockholders Equity | $80.86M | $90.34M | $102.59M | $115.16M | $129.42M | $139.94M | $153.38M | $167.79M | $184.16M | $189.91M | $206.37M | $222.75M | $242.39M | $257.82M | $275.36M | $290.96M | $306.64M | $316.08M | $333.49M | $343.47M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $80.86M | $90.34M | $102.59M | $115.16M | $129.42M | $139.94M | $153.38M | $167.79M | $184.16M | $189.91M | $206.37M | $222.75M | $242.39M | $257.82M | $275.36M | $290.96M | $306.64M | $316.08M | $333.49M | $343.47M |
| Total Investments | $40.89M | $47.61M | $65.59M | $77.64M | $95.22M | $98.69M | $108.60M | $115.52M | $133.28M | $138.16M | $157.33M | $190.67M | $207.25M | $198.67M | $214.62M | $231.71M | $501.35M | $268.67M | $284.29M | $293.19M |
| Total Debt | $5.95M | $5.39M | $6.16M | $6.62M | $6.61M | $6.12M | $6.29M | $6.45M | $7.12M | $- | $- | $- | $- | $- | $2.64M | $3.06M | $3.47M | $3.89M | $4.31M | $4.72M |
| Net Debt | $-21.78M | $-22.31M | $-14.69M | $-11.73M | $-6.48M | $-13.40M | $-15.73M | $-23.52M | $-19.51M | $-31.05M | $-28.16M | $-10.65M | $-12.34M | $-36.66M | $-32.26M | $-33.47M | $-29.30M | $-18.64M | $-20.74M | $-24.18M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-55.65M | $-62.72M | $-74.73M | $-69.39M | $-36.60M |
| Depreciation and Amortization | $2.87M | $3.68M | $4.12M | $7.20M | $3.41M |
| Deferred Income Tax | $- | $- | $- | $-23.74M | $-12.70M |
| Stock Based Compensation | $6.33M | $8.19M | $9.51M | $10.29M | $7.91M |
| Change in Working Capital | $4.53M | $-1.94M | $3.73M | $-5.34M | $-19.68M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $3.02M | $-1.94M | $2.33M | $-1.96M | $2.04M |
| Other Working Capital | $1.51M | $- | $1.40M | $-3.38M | $-21.71M |
| Other Non Cash Items | $1.12M | $-183.00K | $3.49M | $23.74M | $12.70M |
| Net Cash Provided by Operating Activities | $-40.80M | $-52.97M | $-53.89M | $-57.24M | $-44.95M |
| Investments in Property Plant and Equipment | $-474.00K | $-820.00K | $-2.12M | $-2.36M | $-7.13M |
| Acquisitions Net | $- | $- | $-70.09K | $-38.96K | $-50.66K |
| Purchases of Investments | $-48.45M | $-73.50M | $-34.64M | $-156.48M | $-137.13M |
| Sales Maturities of Investments | $104.23M | $113.60M | $104.74M | $195.44M | $187.78M |
| Other Investing Activities | $- | $- | $70.09K | $38.96K | $50.66K |
| Net Cash Used for Investing Activities | $55.31M | $39.27M | $67.98M | $36.60M | $43.52M |
| Debt Repayment | $- | $- | $- | $-3.47M | $-1.53M |
| Common Stock Issued | $39.00K | $154.00K | $66.00K | $208.00K | $112.00K |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $105.00K | $154.00K | $200.00K | $208.00K | $- |
| Net Cash Used Provided by Financing Activities | $144.00K | $154.00K | $200.00K | $-3.27M | $-1.42M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $14.64M | $-13.55M | $14.29M | $-23.91M | $-2.85M |
| Cash at End of Period | $27.73M | $13.08M | $26.63M | $12.38M | $36.28M |
| Cash at Beginning of Period | $13.08M | $26.63M | $12.34M | $36.28M | $39.13M |
| Operating Cash Flow | $-40.80M | $-52.97M | $-53.89M | $-57.24M | $-44.95M |
| Capital Expenditure | $-474.00K | $-820.00K | $-2.12M | $-2.36M | $-7.13M |
| Free Cash Flow | $-41.28M | $-53.79M | $-56.00M | $-59.60M | $-52.09M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-11.60M | $-11.54M | $-15.40M | $-17.11M | $-14.47M | $-14.30M | $-17.86M | $-16.10M | $-17.30M | $-18.91M | $-17.92M | $-20.60M | $-16.94M | $-17.93M | $-17.99M | $-16.53M | $-15.46M | $-16.37M | $-14.51M | $9.73M |
| Depreciation and Amortization | $674.00K | $700.00K | $701.00K | $940.00K | $824.00K | $946.00K | $954.00K | $960.00K | $1.01M | $1.02M | $-1.00K | $2.10M | $2.10M | $2.10M | $1.89M | $1.10M | $990.00K | $885.00K | $787.00K | $751.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-3.90M | $-318.00K | $-196.00K | $- | $- | $- | $- | $- | $-52.45M | $- | $- | $- | $19.68M | $- | $- | $- |
| Stock Based Compensation | $1.52M | $1.53M | $1.59M | $1.69M | $1.98M | $2.00M | $2.12M | $2.08M | $2.33M | $2.31M | $2.24M | $2.63M | $2.51M | $2.48M | $2.79M | $2.51M | $2.34M | $2.37M | $2.19M | $1.01M |
| Change in Working Capital | $2.58M | $-1.95M | $3.51M | $385.00K | $1.17M | $-1.25M | $97.00K | $-1.95M | $4.12M | $-111.00K | $-716.00K | $430.00K | $-1.12M | $689.00K | $-3.91M | $-991.00K | $5.85M | $-2.56M | $-875.00K | $-22.09M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $1.74M | $-1.46M | $584.00K | $2.16M | $-272.00K | $-211.00K | $894.00K | $-2.35M | $2.42M | $-425.00K | $-529.00K | $859.00K | $-1.00M | $1.59M | $-666.00K | $-1.88M | $3.71M | $-2.25M | $172.00K | $402.00K |
| Other Working Capital | $845.00K | $-486.00K | $2.93M | $-1.78M | $1.44M | $-1.04M | $-797.00K | $398.00K | $1.70M | $314.00K | $-187.00K | $-429.00K | $-119.00K | $-906.00K | $-3.25M | $893.00K | $2.13M | $-314.00K | $-1.05M | $-22.49M |
| Other Non Cash Items | $-144.00K | $-195.00K | $2.23M | $2.90M | $3.73M | $144.00K | $132.00K | $232.00K | $896.00K | $688.00K | $1.91M | $5.96M | $52.45M | $5.08M | $7.24M | $6.60M | $-19.68M | $-2.25K | $172 | $-21.98K |
| Net Cash Provided by Operating Activities | $-6.97M | $-11.45M | $-9.78M | $-12.61M | $-10.67M | $-12.78M | $-14.75M | $-14.78M | $-8.95M | $-15.00M | $-14.49M | $-15.45M | $-13.45M | $-12.66M | $-17.22M | $-13.91M | $-6.28M | $-15.67M | $-12.41M | $-10.59M |
| Investments in Property Plant and Equipment | $34.00K | $-170.00K | $-301.00K | $-37.00K | $-13.00K | $-279.00K | $-280.00K | $-248.00K | $-865.00K | $-532.00K | $-414.00K | $-305.00K | $-825.00K | $-556.00K | $-213.00K | $-766.00K | $-980.00K | $-1.87M | $-2.83M | $-1.45M |
| Acquisitions Net | $- | $- | $- | $- | $-4.17K | $- | $-6.99K | $-18.37K | $- | $-18.42K | $-32.34K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-8.34M | $-6.53M | $-22.45M | $-11.14M | $-11.82M | $- | $-30.29M | $-31.40M | $-21.38M | $-5.38M | $-7.89M | $- | $-34.58M | $-19.64M | $-63.84M | $-38.42M | $-41.14M | $-42.63M | $-29.83M | $-23.53M |
| Sales Maturities of Investments | $15.26M | $25.00M | $34.91M | $29.05M | $15.99M | $10.56M | $37.27M | $49.77M | $26.71M | $23.80M | $40.22M | $14.01M | $24.40M | $34.61M | $79.64M | $56.79M | $58.62M | $57.60M | $41.22M | $30.35M |
| Other Investing Activities | $- | $- | $12.46K | $17.92K | $4.17K | $10.56K | $6.99K | $18.37K | $- | $18.42K | $32.34K | $14.01K | $-10.18K | $14.97K | $15.80K | $18.37K | $17.48K | $14.98K | $11.38K | $6.82K |
| Net Cash Used for Investing Activities | $6.96M | $18.31M | $12.16M | $17.88M | $4.16M | $10.28M | $6.71M | $18.12M | $4.47M | $17.89M | $31.92M | $13.70M | $-11.00M | $14.41M | $15.59M | $17.60M | $16.50M | $13.10M | $8.55M | $5.37M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-2.64M | $-417.00K | $-417.00K | $-416.00K | $-417.00K | $-417.00K | $-277.00K |
| Common Stock Issued | $- | $-107.00K | $106.00K | $1.00K | $71.00K | $- | $83.00K | $- | $- | $- | $79.00K | $60.00K | $123.00K | $9.00K | $13.00K | $63.00K | $18.00K | $54.00K | $3.00K | $37.00K |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $36.00K | $1.00K | $106.00K | $1.00K | $71.00K | $- | $83.00K | $- | $61.00K | $- | $79.00K | $60.00K | $123.00K | $- | $- | $- | $- | $54.00K | $- | $- |
| Net Cash Used Provided by Financing Activities | $36.00K | $1.00K | $106.00K | $1.00K | $71.00K | $- | $83.00K | $- | $61.00K | $- | $79.00K | $60.00K | $123.00K | $-2.63M | $-404.00K | $-354.00K | $-398.00K | $-363.00K | $-414.00K | $-240.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $25.00K | $6.85M | $2.49M | $5.28M | $-6.44M | $-2.50M | $-7.95M | $3.34M | $-4.46M | $2.89M | $17.51M | $-1.69M | $-24.33M | $-878.00K | $-2.04M | $3.33M | $9.82M | $-2.93M | $-4.27M | $-5.46M |
| Cash at End of Period | $27.73M | $27.70M | $20.85M | $18.36M | $13.08M | $19.52M | $22.02M | $29.97M | $26.63M | $31.09M | $28.20M | $10.69M | $12.38M | $36.70M | $37.58M | $39.62M | $36.28M | $26.46M | $29.39M | $33.67M |
| Cash at Beginning of Period | $27.70M | $20.85M | $18.36M | $13.08M | $19.52M | $22.02M | $29.97M | $26.63M | $31.09M | $28.20M | $10.69M | $12.38M | $36.70M | $37.58M | $39.62M | $36.28M | $26.46M | $29.39M | $33.67M | $39.13M |
| Operating Cash Flow | $-6.97M | $-11.45M | $-9.78M | $-12.61M | $-10.67M | $-12.78M | $-14.75M | $-14.78M | $-8.95M | $-15.00M | $-14.49M | $-15.45M | $-13.45M | $-12.66M | $-17.22M | $-13.91M | $-6.28M | $-15.67M | $-12.41M | $-10.59M |
| Capital Expenditure | $34.00K | $-170.00K | $-301.00K | $-37.00K | $-13.00K | $-279.00K | $-280.00K | $-248.00K | $-865.00K | $-532.00K | $-414.00K | $-305.00K | $-825.00K | $-556.00K | $-213.00K | $-766.00K | $-980.00K | $-1.87M | $-2.83M | $-1.45M |
| Free Cash Flow | $-6.93M | $-11.62M | $-10.08M | $-12.64M | $-10.68M | $-13.06M | $-15.03M | $-15.03M | $-9.81M | $-15.53M | $-14.90M | $-15.75M | $-14.27M | $-13.22M | $-17.43M | $-14.68M | $-7.26M | $-17.55M | $-15.24M | $-12.04M |
NextCure Dividends
Explore NextCure's dividend history, including dividend yield, payout ratio, and historical payments.
NextCure News
Read the latest news about NextCure, including recent articles, headlines, and updates.
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, at 8:45 am ET.
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
BELTSVILLE, Md., March 06, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported full year 2024 financial results.
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced the first patient has been dosed in its Phase 1 study of LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) as a therapeutic for treating multiple cancers.
NextCure Announces Acceptance of IND Application for LNCB74
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference in New York City on Thursday, December 5, at 12:00 pm ET.
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
BELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 (S15) antibody, resulted in enhanced generation of quality bone with better mechanical properties, in an oral presentation at the Osteogenesis Imperfecta Federation Europe virtual Investigator Meeting on November 15th, 2024. These results demonstrate that NC605 is a highly effective treatment for Osteogenesis Imperfecta (OI), also known as brittle bone disease in a well-established model of disease.
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
BELTSVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported third-quarter 2024 financial results.
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
BELTSVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today reports pre-clinical data from LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) being developed in partnership with LigaChem Biosciences (LCB) (KOSDAQ: 141080), and biomarker data from the NC410 combination study with pembrolizumab in patients with immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC). The data will be presented during poster sessions at the Society for Immunotherapy of Cancer (SITC) annual meeting.
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Houston, TX from November 6-10, 2024. NextCure will share pre-clinical data from LNCB74 (B7-H4 ADC) and biomarker data from NC410 combination study with pembrolizumab in ICI-naïve MSS/MSI-L CRC during poster sessions.
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
BELTSVILLE, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab was presented at ESMO 2024. The trial, which is evaluating the combination in ovarian cancer and immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC), demonstrated clinical activity in these hard-to-treat cancers. The data were presented by clinical trial investigators Emese Zsiros, M.D., Ph.D., Associate Professor of Oncology, Chair, Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center (ovarian) and Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (CRC). The presentations are available on the NextCure website (www.nextcure.com).
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024.
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
BELTSVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The trial evaluated the combination in immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer and demonstrated clinical activity in these hard-to-treat cancers. The data will be presented in a poster session by clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
BELTSVILLE, Md., May 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported its first-quarter 2024 financial results.
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S.
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4.
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11th, at 12:45 pm ET.
Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
The bullish sentiment in the market is leading some investors to look at risk-on assets. Bitcoin may be an option, but for investors who prefer to stay in stocks, it may be time to look for some of the analysts' favorite penny stocks.
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
BELTSVILLE, Md. – March 21, 2024, March 21, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer today provided a business update and reported full year 2023 financial results.
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
BELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “The FLRT3-UNC5B Checkpoint Pathway Inhibits T Cell-Based Cancer Immunotherapies” in the journal Science Advances, published by the American Association for the Advancement of Science. The publication details preclinical data evaluating the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) in the inhibition of T cell activity and the use of a monoclonal antibody to reverse these effects.
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
BELTSVILLE, Md., Jan. 18, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of preclinical data relating to a novel humanized monoclonal antibody targeting VSTM-1, for the treatment of progressive inflammatory airway disorders, including chronic obstructive pulmonary disease (COPD), at the Keystone Symposium for Inhibitory Receptors in Immune Homeostasis, Disease and Therapy.
Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing
NextCure, Inc. (NXTC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
BELTSVILLE, Md., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “Anti-Siglec-15 Antibody Prevents Marked Bone Loss after Acute Spinal Cord Injury-Induced Immobilization in Rats” in JMBR Plus, a journal of the American Society for Bone and Mineral Research (ASBMR). The data demonstrated that NC605, a novel anti-Siglec-15 (S15) antibody, prevented bone loss, but more importantly preserved bone strength in animal models of severe immobilization resulting from acute spinal cord injury.
NextCure Provides Year-End Clinical Pipeline Updates
BELTSVILLE, Md., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on its clinical pipeline.
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
BELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference in New York City on Thursday, November 30th, at 1:30 pm ET.
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
BELTSVILLE, Md., Nov. 15, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “LAIR-1 Agonism as a Therapy for Acute Myeloid Leukemia” in the Journal of Clinical Investigation. The data demonstrate that NC525 induces cell death in acute myeloid leukemia (AML) blast cells and leukemic stem cells (LSCs) through leukocyte-associated immunoglobin-like receptor-1 (LAIR-1) agonism by driving a unique apoptotic signaling pathway.
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
BELTSVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported third quarter 2023 financial results.
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for NXTC.